- Home
- BMEA vs UBFO Comparison
BMEA vs UBFO Comparison
Compare BMEA & UBFO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- UBFO
- Stock Information
- Founded
- BMEA 2017
- UBFO 1987
- Country
- BMEA United States
- UBFO United States
- Employees
- BMEA N/A
- UBFO N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- UBFO Major Banks
- Sector
- BMEA Health Care
- UBFO Finance
- Exchange
- BMEA Nasdaq
- UBFO Nasdaq
- Market Cap
- BMEA 65.8M
- UBFO 162.0M
- IPO Year
- BMEA 2021
- UBFO N/A
- Fundamental
- Price
- BMEA $1.94
- UBFO $8.78
- Analyst Decision
- BMEA Strong Buy
- UBFO
- Analyst Count
- BMEA 10
- UBFO 0
- Target Price
- BMEA $22.30
- UBFO N/A
- AVG Volume (30 Days)
- BMEA 2.2M
- UBFO 114.7K
- Earning Date
- BMEA 07-30-2025
- UBFO 07-21-2025
- Dividend Yield
- BMEA N/A
- UBFO 5.49%
- EPS Growth
- BMEA N/A
- UBFO N/A
- EPS
- BMEA N/A
- UBFO 0.77
- Revenue
- BMEA N/A
- UBFO $47,362,000.00
- Revenue This Year
- BMEA N/A
- UBFO N/A
- Revenue Next Year
- BMEA N/A
- UBFO N/A
- P/E Ratio
- BMEA N/A
- UBFO $11.33
- Revenue Growth
- BMEA N/A
- UBFO N/A
- 52 Week Low
- BMEA $1.29
- UBFO $7.27
- 52 Week High
- BMEA $13.07
- UBFO $10.49
- Technical
- Relative Strength Index (RSI)
- BMEA 49.92
- UBFO 51.35
- Support Level
- BMEA $1.58
- UBFO $8.83
- Resistance Level
- BMEA $2.01
- UBFO $9.28
- Average True Range (ATR)
- BMEA 0.15
- UBFO 0.28
- MACD
- BMEA 0.01
- UBFO 0.04
- Stochastic Oscillator
- BMEA 80.00
- UBFO 57.02
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About UBFO United Security Bancshares
United Security Bancshares operates as the holding for United Security Bank. It provides commercial banking services to the business and professional community, and individuals located in Fresno, Madera, Santa Clara, and Kern Counties. It offers checking and savings accounts, deposits, mortgage loans, credit and debit cards, safe deposit boxes, automated teller machines, wire transfers, money market accounts, mobile banking, and wealth management services. The company's primary sources of revenue are interest income from loans and investment securities.